Clinical Trial of Umbilical Cord Mesenchymal Stem Cell Transfusion in Decompensated Liver Cirrhosis


Shandong Qilu Stem Cells Engineering

Status and phase

Phase 2


Decompensated Liver Cirrhosis


Biological: UC-MSC

Study type


Funder types




Details and patient eligibility


Decompensated liver cirrhosis is one of the life-threatening complication of chronic liver disease. Liver transplantation currently is the only effective method that can improve the survival of these patients. However, the severe shortage of donor livers, high cost, and potential serious complications have restricted the availability of liver transplantation.Umbilical cord mesenchymal stem cells (UC-MSC) has been generally shown to be safe and effective for liver diseases in some pre-clinical and clinical studies. This study aim to evaluate the safety and efficiency of human umbilical cord mesenchymal stem cell transfusion in patients with decompensated liver cirrhosis, and explore the best protocol of MSC transfusion.

Full description

This study is a multicenter non randomized control study. Patients with decompensated liver cirrhosis are going to be assigned to receive standard medical care plus UC-MSC treatment with two different protocol (group 1 and group 2) or standard medical care (control). Four times of MSC infusion (1.5x10E6 cells/kg body weight) via peripheral vein will be given to the group 1(once every 4 days), and two times of MSC infusion once every 7 days to the group 2. The primary outcome is survival rates in one year. Secondary outcomes are liver function, liver ascites and MELD score.


252 estimated patients




18 to 65 years old


No Healthy Volunteers

Inclusion criteria

  1. Clinically diagnosed as decompensated liver cirrhosis.
  2. Hepatitis B/C Liver Cirrhosis After Viral Treatment, HBV/HCV Viral Loads Below Detection Level over six mouths, and the liver function remained below Child-pugh A grade or MELD score >10.
  3. Other causes of cirrhosis, liver function compensatory incomplete.
  4. In the past year, despite active medical treatment taken, the condition has continued to increase, at least because of cirrhosis complications such as ascites, spontaneous peritonitis, gastrointestinal bleeding, and hepatic encephalopathy in hospital over one time.
  5. Need to intermittently supplement albumin and apply diuretic therapy.
  6. Albumin <35 g/L, total bilirubin <170 umol/L, prothrombin activity> 30%; (Prothrombin time <20 s, moderate or lower mass ascites, spontaneous peritonitis and hepatic encephalopathy (grade II or lower), Child-pugh score> 5 points).
  7. There was no history of gastrointestinal hemorrhage within the last month and population with no high-risk portal hypertension and gastrointestinal bleeding was evaluated recently.
  8. Unconditional acceptance of orthotopic liver transplantation.
  9. Aged from 18 to 65 years.
  10. Voluntarily signed informed consent form.

Exclusion criteria

  1. A malignant tumor with liver or other organs or a history of previous cancer.

  2. Complications include gastrointestinal bleeding, spontaneous peritonitis, hepatic encephalopathy, hepatorenal syndrome, and Acute infection episodes.

  3. Patients with severe heart, lung, kidney or blood system diseases and failure status.

  4. Pregnant or lactating women.

  5. Allergic constitution.

  6. There is a history of alcohol abuse, drug abuse, and failure to effectively quit. 7. Patients did not participate in other clinical trials within 4 weeks.

  7. Any condition, investigator believe that patients should not participate in this study.

Trial design

Primary purpose




Interventional model

Parallel Assignment


None (Open label)

252 participants in 3 patient groups

MSC group 1
Experimental group
Procedure:UC-MSC infusion via peripheral vein. Four times of MSC infusion (1.5x10E6 cells/kg body weight) via peripheral vein will be given to the group 1(once every 4 days).
Biological: UC-MSC
MSC group 2
Experimental group
Procedure:UC-MSC infusion via peripheral vein. Two times of MSC infusion (1.5x10E6 cells/kg body weight) via peripheral vein will be given to the group 2(once every 7 days).
Biological: UC-MSC
Control group
Experimental group
Control group with standard medical care. UC-MSC infusion could be considering in this group after 24 weeks' followed-up.
Biological: UC-MSC

Trial contacts and locations



Central trial contact


Data sourced from

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems